Sanofi Consumer Healthcare India reports robust Q4 and FY’25 growth
For the fourth quarter, revenue surged 47% year-on-year to Rs. 2,510 million, driven by a 23% rise in domestic sales and a 9.3x jump in export sales
For the fourth quarter, revenue surged 47% year-on-year to Rs. 2,510 million, driven by a 23% rise in domestic sales and a 9.3x jump in export sales
Brivaracetam Oral Solution (10 mg/mL) is a prescription antiepileptic drug (anticonvulsant) used for treatment of partial-onset seizures in patients 1 month of age and older
New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform
The announcement follows a record-setting $1.2 million accelerated LineaDNA order
Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management
Meenal brings in more than 16 years of international experience across Europe, Asia and the Middle East
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
Merck is currently conducting approximately 80 Phase 3 studies, and the company expects more than 20 new growth drivers over next several years, almost all with blockbuster potential
Subscribe To Our Newsletter & Stay Updated